SCHEMBL20147396

SCHEMBL20147396

CC(C)N1CCC(Cc2ccccc2)(NC(=O)CO)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
ADRB2 P07550 2/20 0.46
HTT P42858 1/20 0.46
DPP4 P27487 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CHRM1 P11229 2/20 0.42
CYP2D6 P10635 1/20 0.42
RET P07949 1/20 0.42
HRH3 Q9Y5N1 2/20 0.41
KCNH2 Q12809 1/20 0.41
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
GAA P10253 1/20 0.39
KDM4E B2RXH2 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20147403 0.90 ALDH1A1 (0.44) ALDH1A1ADRB2HTTDPP4MEN1
SCHEMBL20147384 0.88 DPP4 (0.48) ALDH1A1ADRB2HTTDPP4MEN1
SCHEMBL20147377 0.87 CYP2D6 (0.44) ALDH1A1ADRB2HTTDPP4MEN1
SCHEMBL20147409 0.86 RET (0.44) ALDH1A1ADRB2HTTDPP4MEN1
SCHEMBL20147395 0.85 RET (0.45) ALDH1A1ADRB2HTTDPP4MEN1
SCHEMBL20069608 0.85 ADRB2 (0.49) ALDH1A1ADRB2HTTDPP4RET
SCHEMBL25499853 0.84 DPP4 (0.48) ALDH1A1ADRB2HTTDPP4MEN1
SCHEMBL20147407 0.84 DPP4 (0.46) ALDH1A1ADRB2HTTDPP4MEN1
SCHEMBL20147419 0.84 RET (0.46) ALDH1A1ADRB2HTTDPP4MEN1
SCHEMBL20147397 0.82 RET (0.43) ALDH1A1ADRB2HTTDPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 ALDH1A1 2547/4885ADRB2 3956/4885HTT 3338/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 ALDH1A1 2547/4885ADRB2 3956/4885HTT 3338/4885
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 ALDH1A1 2547/4885ADRB2 3956/4885HTT 3338/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 ALDH1A1 2547/4885ADRB2 3956/4885HTT 3338/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 ALDH1A1 2547/4885ADRB2 3956/4885HTT 3338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.